Explore 3 Stock Ideas & Industry Insights Download Free Report

Amarantus Bioscience Holdings Inc

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
7020
Market Cap
0.01M

Momentum Score

…

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
-
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Amarantus Bioscience Holdings is a small-cap biotechnology company listed on the OTC Pink that develops therapeutic and diagnostic candidates for neurological and neurodegenerative disorders. Long-term growth drivers include progress through clinical and regulatory milestones, potential licensing or collaboration opportunities, and demographic trends increasing demand for relevant diagnostics and treatments, which may benefit shareholders if programs advance.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.78
ROE
-
Net Debt
19.14M
ROCE
19.31%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -4.76M -10.20M -0.63M 18.38M -10.58M
Net income -4.76M -10.20M -0.63M 18.38M -10.58M
Selling general administrative - - - - 3.04M
Gross profit 0.10M - 0.07M 20.00M -
Ebit -4.76M -10.20M -0.63M 18.38M -3.04M
Ebitda -4.53M -9.96M -0.42M 18.55M -
Depreciation and amortization 0.23M 0.24M 0.21M 0.17M -
Operating income -0.27M -0.15M -0.63M 18.33M -3.04M
Other operating expenses 0.36M 0.15M 0.70M 1.67M -
Interest expense - - - - 0.00M
Income tax expense -0.23M - - - -
Total revenue 0.10M - 0.07M 20.00M -
Total operating expenses 0.36M 0.15M 0.70M 1.67M 3.04M
Total other income expense net -4.49M -10.05M 0.00M 0.05M -7.54M
Net income from continuing ops - - - - -10.58M
Net income applicable to common shares - - - - -10.58M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 10.21M 14.71M 24.87M 24.79M 3.48M
Intangible assets 0.00M 0.00M 0.00M 0.00M 0.00M
Other current assets 0.03M 0.03M 0.03M 0.03M -
Total liab 34.87M 34.63M 34.36M 33.74M 31.39M
Total stockholder equity -24.67M -19.93M -9.48M -8.96M -30.76M
Other current liab 0.42M -15.44M -15.16M -14.60M -
Common stock 0.29M 0.28M 0.27M 0.26M 0.22M
Retained earnings -106.47M -101.65M -91.25M -90.62M -115.60M
Cash - 0.00M 0.00M 0.00M 0.00M
Total current liabilities 34.87M 34.63M 34.36M 33.74M 31.39M
Net debt 19.14M 19.19M 19.20M 19.14M -
Short term debt 19.14M 19.19M 19.20M 19.14M -
Short long term debt total 19.14M 19.19M 19.20M 19.14M -
Other stockholder equity 80.28M 80.19M 80.23M 80.11M -
Total current assets 0.03M 0.03M 0.03M 0.03M 0.75M
Long term investments - - - - 2.73M
Net tangible assets - - - - -30.77M
Net receivables - - - - 0.03M
Accounts payable 15.31M 15.44M 15.16M 14.60M 12.73M
Accumulated other comprehensive income -0.29M -0.28M -0.27M -0.26M -
Non current assets total 10.18M 14.68M 24.84M 24.75M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - - - 6.07M
Change to liabilities - - - - 0.70M
Total cashflows from investing activities 4.50M 9.97M -0.08M -2.03M 6.07M
Net borrowings - - - - 7.89M
Total cash from financing activities - -0.05M 0.16M 1.01M -4.33M
Change to operating activities - - - - 0.57M
Net income -4.76M -10.20M -0.63M 18.38M -10.58M
Change in cash -0.00M 0.00M -0.00M -0.00M -0.05M
Begin period cash flow 0.00M 0.00M 0.00M 0.00M -
End period cash flow - 0.00M 0.00M 0.00M -
Total cash from operating activities -4.50M -9.93M -0.08M 1.02M -1.80M
Other cashflows from investing activities 4.50M 9.97M -0.08M - -
Change to account receivables 0.06M 0.21M 0.07M - -
Other cashflows from financing activities 4.50M -0.05M 0.09M 0.06M -2.96M
Change to netincome - - - - 7.52M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.24M 0.27M 0.55M -17.36M -
Other non cash items 0.02M -0.27M -0.55M -0.72M -
Free cash flow -4.50M -9.93M -0.08M 1.02M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
AMBS
Amarantus Bioscience Holdings Inc
-
-%
0.00 - - - 53.19 -0.40
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Amarantus Bioscience Holdings Inc

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

45 Wall Street, New York, NY, United States, 10005

650-862-5391

Name Title Year Born
Mr. Gerald E. Commissiong CEO, Pres & Director 1983
Dr. John Wesley Commissiong Chief Scientific Officer, Director & Member of Scientific Advisory Board 1945
Mr. Robert Lewis Harris Compliance Officer & Director 1944
Dr. Elise Brownell M.S., Ph.D. Sr. VP of Operations & Project Management NA
Aimee Boutcher Director of Investor Relations NA
Dr. Ravi Kiron Sr. VP of Bus. Devel. 1960
Dr. Paula T. Trzepacz M.D. Chief Medical Advisor to Elto Pharma and Breakthrough Diagnostics NA
Dr. Brian E. Harvey Chief Regulatory Advisor & Member of Board of Advisors NA
Dr. Richard Kagan M.D. Chief Medical Advisor to Cutanogen Corp. NA
Dr. Owen Garrick Corp. Advisor NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…